Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Long-Term Deferred Tax readings, the most recent being $193.6 million for Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax fell 6.98% to $193.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $193.6 million, a 6.98% decrease, with the full-year FY2025 number at $198.1 million, down 6.16% from a year prior.
  • Long-Term Deferred Tax hit $193.6 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $198.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $219.3 million in Q4 2023 to a low of $184.4 million in Q1 2023.
  • Median Long-Term Deferred Tax over the past 5 years was $203.9 million (2023), compared with a mean of $201.2 million.
  • Biggest five-year swings in Long-Term Deferred Tax: grew 18.22% in 2023 and later decreased 6.98% in 2026.
  • Kiniksa Pharmaceuticals International's Long-Term Deferred Tax stood at $185.5 million in 2022, then increased by 18.22% to $219.3 million in 2023, then dropped by 3.71% to $211.2 million in 2024, then dropped by 6.16% to $198.1 million in 2025, then decreased by 2.28% to $193.6 million in 2026.
  • The last three reported values for Long-Term Deferred Tax were $193.6 million (Q1 2026), $198.1 million (Q4 2025), and $201.3 million (Q3 2025) per Business Quant data.